- Home
- JANX vs RPD Comparison
JANX vs RPD Comparison
Compare JANX & RPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- RPD
- Stock Information
- Founded
- JANX 2017
- RPD 2000
- Country
- JANX United States
- RPD United States
- Employees
- JANX N/A
- RPD N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- RPD Computer Software: Prepackaged Software
- Sector
- JANX Health Care
- RPD Technology
- Exchange
- JANX Nasdaq
- RPD Nasdaq
- Market Cap
- JANX 1.4B
- RPD 1.3B
- IPO Year
- JANX 2021
- RPD 2015
- Fundamental
- Price
- JANX $23.15
- RPD $19.38
- Analyst Decision
- JANX Strong Buy
- RPD Hold
- Analyst Count
- JANX 11
- RPD 19
- Target Price
- JANX $76.55
- RPD $27.00
- AVG Volume (30 Days)
- JANX 714.6K
- RPD 977.2K
- Earning Date
- JANX 11-05-2025
- RPD 11-05-2025
- Dividend Yield
- JANX N/A
- RPD N/A
- EPS Growth
- JANX N/A
- RPD N/A
- EPS
- JANX N/A
- RPD 0.43
- Revenue
- JANX $439,000.00
- RPD $855,361,000.00
- Revenue This Year
- JANX N/A
- RPD $2.75
- Revenue Next Year
- JANX $130.50
- RPD $3.21
- P/E Ratio
- JANX N/A
- RPD $44.94
- Revenue Growth
- JANX N/A
- RPD 4.67
- 52 Week Low
- JANX $21.73
- RPD $17.83
- 52 Week High
- JANX $71.71
- RPD $44.48
- Technical
- Relative Strength Index (RSI)
- JANX 48.91
- RPD 42.64
- Support Level
- JANX $21.73
- RPD $19.05
- Resistance Level
- JANX $24.54
- RPD $20.95
- Average True Range (ATR)
- JANX 1.07
- RPD 0.69
- MACD
- JANX -0.06
- RPD -0.02
- Stochastic Oscillator
- JANX 47.38
- RPD 15.53
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.